CR20120271A - Composiciones lipopéptidas y métodos relacionados - Google Patents

Composiciones lipopéptidas y métodos relacionados

Info

Publication number
CR20120271A
CR20120271A CR20120271A CR20120271A CR20120271A CR 20120271 A CR20120271 A CR 20120271A CR 20120271 A CR20120271 A CR 20120271A CR 20120271 A CR20120271 A CR 20120271A CR 20120271 A CR20120271 A CR 20120271A
Authority
CR
Costa Rica
Prior art keywords
related methods
lipopeptide compositions
lipopeptide
compositions
present disclosure
Prior art date
Application number
CR20120271A
Other languages
English (en)
Inventor
Sandra O'connor
Sophie Sun
Gaauri Naik
Original Assignee
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44060422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120271(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharm Inc filed Critical Cubist Pharm Inc
Publication of CR20120271A publication Critical patent/CR20120271A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgaciòn brinda formulaciones de daptomicina en polvo novedosas que han mejorado la estabilidad quìmica y acelerado los tiempos de reconstituciòn, cuando estàn en estado sòlido.
CR20120271A 2009-11-23 2012-05-22 Composiciones lipopéptidas y métodos relacionados CR20120271A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26378409P 2009-11-23 2009-11-23

Publications (1)

Publication Number Publication Date
CR20120271A true CR20120271A (es) 2012-08-01

Family

ID=44060422

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120271A CR20120271A (es) 2009-11-23 2012-05-22 Composiciones lipopéptidas y métodos relacionados

Country Status (33)

Country Link
US (3) US8835382B2 (es)
EP (2) EP3417849A1 (es)
JP (3) JP6041673B2 (es)
CN (3) CN102712677B (es)
AR (2) AR079127A1 (es)
AU (1) AU2010321531C1 (es)
BR (1) BR112012012406B1 (es)
CA (1) CA2781666C (es)
CL (2) CL2012001336A1 (es)
CO (1) CO6541585A2 (es)
CR (1) CR20120271A (es)
CY (1) CY1120854T1 (es)
DK (1) DK2504353T4 (es)
DO (1) DOP2012000140A (es)
EC (1) ECSP12011939A (es)
ES (1) ES2686331T5 (es)
FI (1) FI2504353T4 (es)
HR (1) HRP20181380T4 (es)
HU (1) HUE039967T2 (es)
IL (1) IL219891B (es)
LT (1) LT2504353T (es)
MX (1) MX2012005993A (es)
NZ (1) NZ600118A (es)
PE (2) PE20151717A1 (es)
PL (1) PL2504353T5 (es)
PT (1) PT2504353T (es)
RS (1) RS57566B2 (es)
RU (1) RU2607526C2 (es)
SG (1) SG10201407724YA (es)
SI (1) SI2504353T2 (es)
TR (1) TR201812823T4 (es)
TW (2) TWI548414B (es)
WO (1) WO2011063419A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
SG10201407724YA (en) 2009-11-23 2014-12-30 Cubist Pharm Inc Daptomycin compositions and related methods
CN103429228B (zh) 2011-01-05 2016-10-26 赫士睿股份有限公司 万古霉素的喷雾干燥
MX2013013760A (es) * 2011-05-26 2014-01-08 Cubist Pharm Inc Composiciones de cb-183, 315 y metodos relacionados.
EP2802340B1 (en) * 2012-01-12 2020-10-28 Celgene Corporation Romidepsin formulations and uses thereof
NO2887953T3 (es) * 2012-08-23 2018-03-10
HK1207006A1 (en) 2012-09-11 2016-01-22 Hospira Australia Pty Ltd Daptomycin formulations and uses thereof
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
CN104511011A (zh) * 2013-09-29 2015-04-15 山东新时代药业有限公司 一种达托霉素无菌粉末及其制备方法
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US10933019B2 (en) 2016-10-21 2021-03-02 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
CN118766886A (zh) * 2017-08-31 2024-10-15 埃克斯利亚制药有限公司 达托霉素制剂
CN110339341A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素或其盐的组合物
CN110548130A (zh) * 2018-06-04 2019-12-10 浙江医药股份有限公司新昌制药厂 含达托霉素的喷雾干粉及其工业化制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
CN111840511A (zh) * 2019-04-30 2020-10-30 江苏恒瑞医药股份有限公司 一种含有精氨酸的达托霉素或其盐的组合物
JP7582205B2 (ja) * 2019-12-26 2024-11-13 ニプロ株式会社 ダプトマイシンを含有する安定した凍結乾燥製剤
CA3168727A1 (en) 2020-02-28 2021-09-02 Barbara FUMIC Daptomycin formulation with branched aiphatic amino acid
AU2021233893A1 (en) * 2020-03-12 2022-08-25 Baxter Healthcare Sa Daptomycin formulations containing a combination of sorbitol and mannitol
US11362190B2 (en) 2020-05-22 2022-06-14 Raytheon Company Depletion mode high electron mobility field effect transistor (HEMT) semiconductor device having beryllium doped Schottky contact layers
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用
RU2770481C1 (ru) * 2021-06-25 2022-04-18 федеральное государственное автономное образовательное учреждение высшего образования «Казанский (Приволжский) федеральный университет» (ФГАОУ ВО КФУ) Способ получения суммарной фракции липопептидов бактерий Bacillus subtilis MG-8 ВКПМ В-12476 и его использование в качестве профилактического средства от болезней сельскохозяйственных птиц

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331594A (en) 1978-10-16 1982-05-25 Eli Lilly And Company A-21978 Antibiotics and process for their production
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4432487A (en) 1982-01-18 1984-02-21 Chugai Denki Kogyo Kabushiki Kaisha Method of overlaying stainless steel material for decorative articles and ornaments with a precious metal alloy
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
CN1051200A (zh) 1984-10-09 1991-05-08 伊莱利利公司 制备抗菌素a-21978c复合物或因子的方法
CA1319886C (en) 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
CA1315229C (en) 1987-06-10 1993-03-30 Eli Lilly And Company Chromatographic purification process
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
EP0294990A3 (en) 1987-06-10 1990-05-09 Eli Lilly And Company Chromatographic purification process
US5271935A (en) 1988-02-05 1993-12-21 Hoechst Aktiengesellschaft Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical
EP0386951A3 (en) * 1989-03-06 1992-05-20 Eli Lilly And Company An improved diluent formulation for daptomycin
EP0438813B1 (en) 1990-01-26 1997-11-19 Hoechst Aktiengesellschaft A novel antibiotic, Deoxymulundocandin, a process for its production and its use as medicament
JPH04224197A (ja) 1990-12-26 1992-08-13 Fujitsu Ltd 生体高分子結晶化方法および装置
US5336756A (en) 1991-05-01 1994-08-09 Merck & Co., Inc. Process for crystalline cyclic lipopeptides
TW213468B (es) 1991-06-29 1993-09-21 Hoechst Ag
JP2948708B2 (ja) 1991-11-27 1999-09-13 ニューヨーク・ブラッド・センター・インコーポレーテッド フィブロネクチン含有点眼液
JP3421338B2 (ja) 1992-04-20 2003-06-30 アボツト・ラボラトリーズ バンコマイシンの製造方法
TW455591B (en) 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
JPH10212241A (ja) * 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
AU5528198A (en) 1997-12-03 1999-06-16 Immune Response Corporation, The Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
DE122006000049I2 (de) 1998-09-25 2007-11-08 Cubist Pharm Inc Verwendung von Daptomycin
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
AU784812B2 (en) 1999-12-15 2006-06-29 Merck Sharp & Dohme Corp. Lipopeptides as antibacterial agents
US6696412B1 (en) * 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
BR0112393A (pt) * 2000-06-21 2003-07-08 Internat Health Man Associates Composições e processos para aperfeiçoamento de absorção oral de agentes antimicrobiais
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
WO2002059145A1 (en) 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
NZ554405A (en) * 2000-12-18 2009-04-30 Cubist Pharm Inc Method for preparing crystalline and crystal-like forms of purified lipopeptides
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
JP3932272B2 (ja) * 2001-06-28 2007-06-20 明治乳業株式会社 多重ｔ細胞エピトープポリペプチドの酢酸塩組成物
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
IL160169A0 (en) 2001-08-06 2004-07-25 Cubist Pharm Inc Nucleic acid molecules that encode a daptomycin non-ribosomal peptide synthetase and methods for the production thereof
AU2003216726A1 (en) 2002-01-17 2003-07-30 Atofina Supramolecular polymers
US20050084490A1 (en) 2002-07-09 2005-04-21 Point Therapeutics, Inc. Boroproline compound combination therapy
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
JP2005060377A (ja) * 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd インターロイキン−１１含有凍結乾燥製剤
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
EP1848413B1 (en) * 2005-02-14 2014-04-09 Venus Remedies Limited Parenteral combination therapy for infective conditions with drug resistant bacterium
CA2610716A1 (en) 2005-05-31 2006-12-07 Cubist Pharmaceuticals, Inc. Daptomycin for the treatment of biofilm and catheter salvage
CA2611577A1 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
JP5373606B2 (ja) * 2006-07-26 2013-12-18 サンド・アクチエンゲゼルシヤフト カスポファンギン製剤
EP2511844B1 (en) 2006-10-10 2015-08-12 XRpro Sciences, Inc. X-ray microscope
DE102007004968B4 (de) * 2007-01-26 2011-03-10 Heraeus Kulzer Gmbh Revisions-Polymethylmethacrylat-Knochenzement
WO2008102452A1 (ja) * 2007-02-22 2008-08-28 Kringle Pharma Inc. Ｈｇｆ製剤
JP2010530846A (ja) * 2007-06-01 2010-09-16 アコロジックス インコーポレイティッド 高温で安定なペプチド製剤
WO2009002481A1 (en) 2007-06-26 2008-12-31 Merck & Co., Inc. Lyophilized anti-fungal composition
AU2008317307A1 (en) * 2007-10-25 2009-04-30 Novartis Ag Powder conditioning of unit dose drug packages
WO2009144739A1 (en) * 2008-05-26 2009-12-03 Biocon Limited Amorphous daptomycin and a method of purification thereof
WO2011019839A2 (en) 2009-08-12 2011-02-17 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility
US8431539B2 (en) 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
SG10201407724YA (en) 2009-11-23 2014-12-30 Cubist Pharm Inc Daptomycin compositions and related methods
JP2013511522A (ja) 2009-11-23 2013-04-04 イーグル・ファーマシューティカルズ・インコーポレーテッド ダプトマイシン製剤
EP2635307B1 (en) 2010-11-01 2020-07-29 Melinta Subsidiary Corp. Pharmaceutical compositions
JP6013364B2 (ja) 2010-12-23 2016-10-25 アルカーメス ファーマ アイルランド リミテッド マルチプルａｐｉローディングプロドラッグ
GB2501219A (en) 2011-02-04 2013-10-16 Aegis Therapeutics Llc Orally bioavailable peptide drug compositions and methods thereof

Also Published As

Publication number Publication date
WO2011063419A3 (en) 2011-10-13
IL219891B (en) 2018-01-31
JP6239167B2 (ja) 2017-11-29
CA2781666A1 (en) 2011-05-26
AR079127A1 (es) 2011-12-28
LT2504353T (lt) 2018-09-25
ES2686331T3 (es) 2018-10-17
BR112012012406B1 (pt) 2021-11-16
TWI548414B (zh) 2016-09-11
TW201703791A (zh) 2017-02-01
JP2017075186A (ja) 2017-04-20
JP6088681B2 (ja) 2017-03-01
HRP20181380T1 (hr) 2018-10-19
NZ600118A (en) 2014-08-29
DK2504353T3 (en) 2018-09-10
DK2504353T4 (da) 2023-11-20
US8835382B2 (en) 2014-09-16
US20140364380A1 (en) 2014-12-11
CN104056250A (zh) 2014-09-24
CA2781666C (en) 2017-02-21
EP2504353B2 (en) 2023-09-13
RS57566B2 (sr) 2023-12-29
AU2010321531B2 (en) 2016-11-03
EP2504353B1 (en) 2018-07-11
ES2686331T5 (es) 2024-03-27
ECSP12011939A (es) 2012-07-31
PE20151717A1 (es) 2015-11-19
TR201812823T4 (tr) 2019-02-21
CL2012001336A1 (es) 2012-10-05
AU2010321531C1 (en) 2020-10-01
PT2504353T (pt) 2018-10-18
SI2504353T1 (sl) 2018-10-30
JP6041673B2 (ja) 2016-12-14
RU2012126076A (ru) 2013-12-27
US20160030577A1 (en) 2016-02-04
FI2504353T4 (fi) 2023-11-30
PL2504353T3 (pl) 2018-11-30
IL219891A0 (en) 2012-07-31
HUE039967T2 (hu) 2019-02-28
RU2607526C2 (ru) 2017-01-10
MX2012005993A (es) 2012-11-23
AU2010321531A2 (en) 2014-10-30
SG10201407724YA (en) 2014-12-30
PE20121517A1 (es) 2012-11-26
JP2016147874A (ja) 2016-08-18
US20120270772A1 (en) 2012-10-25
EP3417849A1 (en) 2018-12-26
EP2504353A4 (en) 2014-04-02
CN102712677B (zh) 2015-06-03
AU2010321531A1 (en) 2012-06-14
CO6541585A2 (es) 2012-10-16
CL2015002412A1 (es) 2016-02-05
EP2504353A2 (en) 2012-10-03
US9138456B2 (en) 2015-09-22
HRP20181380T4 (hr) 2023-11-10
SI2504353T2 (sl) 2023-11-30
US9662397B2 (en) 2017-05-30
WO2011063419A2 (en) 2011-05-26
RS57566B1 (sr) 2018-10-31
CN108785654A (zh) 2018-11-13
DOP2012000140A (es) 2012-10-30
CN102712677A (zh) 2012-10-03
TW201141506A (en) 2011-12-01
TWI606838B (zh) 2017-12-01
AR123846A2 (es) 2023-01-18
BR112012012406A2 (pt) 2019-12-03
JP2013511557A (ja) 2013-04-04
PL2504353T5 (pl) 2023-11-20
CY1120854T1 (el) 2019-12-11

Similar Documents

Publication Publication Date Title
CR20120271A (es) Composiciones lipopéptidas y métodos relacionados
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MX344021B (es) Composiciones fluidas que comprenden un agente de estructuración.
WO2011142858A3 (en) Chlorotoxin variants, conjugates, and methods for their use
CO6561839A2 (es) Alteracion genómica dirigida
MY169141A (en) Biodegradable compositions, methods and uses thereof
WO2012077120A3 (en) Natural formulations
PH12012500948A1 (en) Oral compositions containing extracts of garcinia mangostana l. and related methods
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
MX2013003365A (es) Composicion farmaceutica.
MX358402B (es) Composiciones y artículos que tienen una fragancia madre y microcápsulas que encapsulan una fragancia secundaria.
EP2657333A4 (en) PIG CIRCOVIRUS OF TYPE 2, IMMUNA COMPOSITION THEREOF, TESTKIT AND USE THEREOF
GEP20156230B (en) Forms of rifaximin and usage thereof
UY32659A (es) Pirazinilpirazoles
UA107822C2 (xx) Визначені триазолопіридини та триазолопіразини, їх композиції та їх застосування
PH12014501158A1 (en) Composition comprising a shelf-life stability component
IN2012DN06714A (es)
GB2516207A (en) Conjugated polymers
EP2245113A4 (en) PHOSPHORESCENT COMPOSITIONS, METHOD FOR PRODUCING THE COMPOSITIONS AND METHOD FOR USE OF THE COMPOUNDS
BR112013015505A2 (pt) composição de copolímero de polipropileno de impacto, e,. formulação de composto carregado
IN2012DN03404A (es)
PL2646520T3 (pl) Kompozycja na bazie 1,1,1,4,4,4-heksafluorobut-2-enu i 3,3,4,4,4-pentafluorobut-1-enu
PH12013501311A1 (en) Polymer systems
PH12014502858A1 (en) Racecadotril lipid compositions
MX344189B (es) Formulaciones de mazindol.